Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Guangzhou Pharma Absorbs Guangzhou Baiyunshan Pharma

publication date: Dec 3, 2012
In a reshuffling of assets, Guangzhou Pharma Holding is combining two of its companies. Guangzhou Pharma Co. (GPC) will acquire the assets of Guangzhou Baiyunshan Pharma. The surviving company, GPC, currently has a market capitalization of $2.2 billion. It is known mainly for its TCM products. Baiyunshan makes APIs for chemical drugs, especially antibiotics, and also produces TCM materials and finished TCM products. Its market capitalization is $1.2 billion. The share prices of both companies dropped 10% today after the purchase was given regulatory approval. More details....

Stock Symbols:  (SHA: 600332) (SHE: 000522)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital